{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-008014","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.525269+00:00","generated_at":"2026-05-24T15:20:37.359884+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"DiaMedica FY2024 net loss $24.4M; cash $44.1M; preeclampsia data Q2 2025","bullets":["Net loss $24.4M ($0.60/sh) vs $19.4M; R&D $19.1M, G&A $7.6M; no revenue.","Cash $44.1M at Dec 31, 2024; runway into Q3 2026; operating cash burn $22.1M.","Preeclampsia Phase 2 topline safety/efficacy data expected Q2 2025; dosing ongoing.","ReMEDy2 AIS trial: DSMB cleared new IV dosing; interim analysis of first 200 patients expected H1 2026.","Appointed Daniel J. O'Connor (former Ambrx CEO) to board in February 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-008014","json":"https://secwatch.observer/filing/0001437749-25-008014.json","markdown":"https://secwatch.observer/filing/0001437749-25-008014.md","text":"https://secwatch.observer/filing/0001437749-25-008014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774925008014/0001437749-25-008014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774925008014/dmtp20250316_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T15:20:37.359884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}